QuantumPharm, Inc. (HK:2228)
:2228
Want to see HK:2228 full AI Analyst Report?
Top Page
QuantumPharm, Inc.
(2228)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$6.50
▼(-37.80% Downside)
Action:Reiterated
Date:04/25/26
The score is held down primarily by persistent operating losses and ongoing cash burn, despite strong recent revenue/gross profit growth and a materially improved balance sheet. Technicals are bearish with the stock trading below major moving averages, and valuation is a further headwind given the very high P/E and no dividend yield provided.
Positive Factors
Strong revenue and gross profit growth
Revenue rose materially (to 781.9M in 2025) with gross profit expanding, signaling improving product-market fit and pricing power. Sustained top-line growth and higher gross margins provide the foundation for durable operating leverage and eventual conversion to positive cash generation.
Negative Factors
Persistent negative operating cash flow
Operating cash flow and free cash flow remain negative despite narrower burn, indicating the business is not yet self-funding. Continued cash deficits require external capital, increasing dilution or refinancing risk and constraining long-term investment flexibility if trends persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and gross profit growth
Revenue rose materially (to 781.9M in 2025) with gross profit expanding, signaling improving product-market fit and pricing power. Sustained top-line growth and higher gross margins provide the foundation for durable operating leverage and eventual conversion to positive cash generation.
Read all positive factors
QuantumPharm, Inc. (2228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$29.03B
Dividend YieldN/A
Average Volume (3M)143.30M
Price to Earnings (P/E)181.2
Beta (1Y)0.93
Revenue Growth200.45%
EPS GrowthN/A
CountryHK
Employees809
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,303,371,600
10 Day Avg. Volume160,836,692
30 Day Avg. Volume143,301,077
Financial Highlights & Ratios
PEG Ratio-2.56
Price to Book (P/B)3.42
Price to Sales (P/S)41.11
P/FCF Ratio-160.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.42Price Target Upside9.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)HK$993.31M
QuantumPharm, Inc. Business Overview & Revenue Model
Company Description
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensi...
QuantumPharm, Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 781.85M | 266.43M | 174.42M | 133.35M | 62.80M |
| Gross Profit | 544.71M | 123.43M | 48.24M | 66.09M | 32.78M |
| EBITDA | 253.59M | -631.38M | -1.78B | -1.38B | -2.11B |
| Net Income | 120.54M | -1.52B | -1.91B | -1.44B | -2.14B |
Balance Sheet | |||||
| Total Assets | 10.22B | 4.35B | 4.01B | 4.32B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 7.07B | 3.10B | 2.83B | 3.47B | 3.83B |
| Total Debt | 443.46M | 148.76M | 11.04B | 9.45B | 7.83B |
| Total Liabilities | 786.95M | 362.43M | 11.25B | 9.63B | 7.99B |
| Stockholders Equity | 9.39B | 3.96B | -7.27B | -5.33B | -3.61B |
Cash Flow | |||||
| Free Cash Flow | -199.96M | -536.79M | -698.20M | -627.83M | -417.42M |
| Operating Cash Flow | -139.62M | -478.68M | -567.56M | -429.10M | -253.75M |
| Investing Cash Flow | -3.87B | 74.09M | 735.58M | -2.76B | -70.47M |
| Financing Cash Flow | 5.43B | 840.00M | -25.89M | 57.99M | 2.48B |
QuantumPharm, Inc. Technical Analysis
Negative
10.45
Price Trends
8.28
Negative
9.34
Negative
10.19
Negative
Market Momentum
-0.44
Negative
36.49
Neutral
68.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Negative. The current price of 10.45 is above the 20-day moving average (MA) of 7.25, above the 50-day MA of 8.28, and above the 200-day MA of 10.19, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 36.49 is Neutral, neither overbought nor oversold. The STOCH value of 68.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2228.
QuantumPharm, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$69.33B | 39.75 | 16.29% | ― | 46.83% | 36.46% | |
60 Neutral | HK$3.11B | -23.86 | -32.00% | ― | 410.53% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | HK$811.10M | -11.78 | -3.55% | ― | -16.30% | -113.19% | |
42 Neutral | HK$29.03B | 181.23 | 1.50% | ― | 200.45% | ― | |
42 Neutral | HK$1.37B | -4.67 | -39.41% | ― | ― | 39.48% | |
42 Neutral | HK$9.84B | -51.04 | -2.97% | ― | 30.48% | 65.41% |
* General Sector Average
HK:2228
QuantumPharm, Inc.
6.75
0.98
16.98%
HK:2268
WuXi XDC Cayman, Inc.
55.00
15.10
37.84%
HK:2502
Henan Jinyuan Hydrogenated Chemicals Co., Ltd. Class H
0.49
0.08
21.25%
HK:2511
Hightide Therapeutics Inc
2.69
-0.07
-2.54%
HK:2498
RoboSense Technology Company., Ltd
20.60
-12.05
-36.91%
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
13.69
-1.35
-8.98%
QuantumPharm, Inc. Corporate Events
XtalPi Strikes US$400 Million GPCR Drug Discovery Pact with Global Biopharma Partner
Jun 9, 2026
XtalPi Holdings Limited has entered a strategic partnership with a leading international biopharmaceutical company to develop best-in-class oral small-molecule therapeutics targeting a complex G protein-coupled receptor implicated in metabolic dis...
XtalPi Launches Up to US$100 Million On-Market Share Buyback
Jun 9, 2026
XtalPi Holdings Limited has approved an on-market share repurchase plan of up to US$100 million, allowing the company to buy back as many as 430,337,176 shares, or up to 10% of its issued share capital, on the open market. The buyback window runs ...
XtalPi Wins U.S. Safety Nod for Oral Peptide, Advances Pan-TEAD Cancer Drug
May 31, 2026
XtalPi has advanced its AI-driven peptide business with Tensotide, an innovative oral peptide ingredient developed on its PepiX platform that has secured Self GRAS certification in the U.S. This recognition, following earlier registrations of its ...
XtalPi Advances AI-Driven DoveTree Drug Collaboration, Unlocking Major Milestone Potential
May 27, 2026
XtalPi Holdings Limited reported strong progress in its collaboration with DoveTree, under which it applies its AI-plus-robotics drug discovery platform to multiple disease targets selected by its partner. DoveTree holds exclusive worldwide develo...
XtalPi Co-founders Extend Lock-up on 12.9% Stake to 2027
May 25, 2026
XtalPi Holdings Limited said its three co-founders and executive directors, Dr. Wen Shuhao, Dr. Ma Jian and Dr. Lai Lipeng, have voluntarily extended the lock-up on a large portion of their shareholdings for an additional 12 months. The new expiry...
XtalPi Wins Shareholder Backing for Capital Mandates and New Governance Framework
May 20, 2026
XtalPi Holdings Limited secured strong shareholder backing at its annual general meeting on 20 May 2026, with investors approving all ordinary and special resolutions, including adoption of the 2025 audited financial statements, re-election of key...
XtalPi’s QuantumPharm Commits RMB356 Million to Low-Risk SPDB Structured Deposits
May 5, 2026
XtalPi Holdings Limited’s subsidiary QuantumPharm Limited has subscribed to a new batch of exchange-rate linked, principal‑guaranteed structured deposits issued by Shanghai Pudong Development Bank, committing RMB356.1 million on 11 Sep...
XtalPi Plans New Share Scheme and Governance Overhaul Ahead of AGM
Apr 17, 2026
XtalPi Holdings Limited will seek shareholder approval at its upcoming annual general meeting to adopt a new share scheme aimed at better aligning directors and employees with the company’s long-term interests. The scheme is designed to stre...
XtalPi Sets 2026 AGM to Seek Shareholder Mandates on Buy-backs and New Issues
Apr 17, 2026
XtalPi Holdings Limited has called its annual general meeting for 20 May 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements for the year ended 31 December 2025 and receive reports from the board and the ...
XtalPi Grants Over 22 Million Equity Awards to Employees to Boost Incentives
Apr 9, 2026
XtalPi Holdings Limited has granted 11,234,290 share options to 137 employees and 10,920,770 restricted share units to 270 employees under its existing equity incentive schemes, with all awards subject to acceptance. The move, which excludes direc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.